A noted researcher, Dr. Pfeffer is credited with introducing the concept that angiotensin-converting enzyme inhibitors could attenuate adverse ventricular remodelling following myocardial infarction and that this use would result in a prolongation of survival and other clinical benefits. Since this initial discovery, he has had a principal role in several practice-changing clinical trials.
In addition to his role as researcher in the field of cardiovascular disease, coronary artery disease, heart failure, diabetes and chronic kidney disease, Marc Pfeffer plays an active role in the academic development of trainees and junior faculty collaborating in trials. Dr. Pfeffer is Senior Associate Editor of Circulation and is a member of the Editorial Board of several other prominent journals.
As an internationally recognized expert in the field of cardiology, in 2006 he was recognized by Science Watch as having the most “Hot Papers” (i.e., highly cited) in all of clinical medicine. He is the recipient of the William Harvey Award of the American Society of Hypertension, the Okamoto Award from Japan’s Vascular Disease Research Foundation, the Clinical Research Prize, the James B. Herrick Award as well as the Distinguished Scientist Award from the American Heart Association. Dr. Pfeffer is an Honorary Fellow of the Royal College of Physicians and Surgeons of Glasgow and is the recipient of an Honorary Doctoral Degree from Sahlgrenska Academy, University of Gothenburg, Sweden.